Olanzapine/sertraline/venlafaxine Reactions 1680, p268 - 2 Dec 2017 Various toxicities: 2 case reports In a case series of three women, two women (a 65-year-old and a 59-year-old) were described, one of them developed nausea during treatment with venlafaxine and olanzapine, and the other women developed worsening of mood, delusions of poisoning and auditory hallucinations, and attempted suicide during sertraline therapy. Case A: A 65-year-old woman, who had recurrent major depression, was started on olanzapine 10mg and venlafaxine 150mg [routes and frequencies not stated], along with lorazepam. She responded well to the treatment; however, during first three days of treatment she experienced nausea, which resolved spontaneously. Case C: A 59-year-old woman, who had recurrent major depression disorder, for which she was hospitalised. She was discharged with high dose sertraline 300mg per day [route not stated], along with trazodone, flurazepam and alprazolam. After seven days of treatment, she was hospitalised for attempted suicide. The worsening of her mood, delusions of poisoning and auditory hallucinations were found to be the motivating factors for her suicide attempt. Gradually, the sertraline dose was tapered and finally discontinued. She was stared on venlafaxine and olanzapine, resulting in quick resolution of symptoms. Author comment: "The combination of venlafaxine and olanzapine was well tolerated, with the exception of nausea during the first three days of treatment which spontaneously disappeared." "[W]e considered the possibility that the prescribed high dosage of sertraline may have induced the patient’s psychotic symptoms." Ghio L, et al. Combined venlafaxine and olanzapine prescription in women with psychotic major depression: A case series. Case Reports in Medicine 2011: 2011. Available from: URL: http://doi.org/10.1155/2011/856903 - Italy 803283941 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals


Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
1 page

Loading next page...
1 Page
Springer International Publishing
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
Publisher site
See Article on Publisher Site

There are no references for this article.

You’re reading a free preview. Subscribe to read the entire article.

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches


Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.



billed annually
Start Free Trial

14-day Free Trial